Company Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics.
The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity.
Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.
The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations.
It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial.
The company was incorporated in 2017 and is headquartered in San Mateo, California.
| Country | United States |
| IPO Date | Oct 9, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Dr. Norbert W. Bischofberger Ph.D. |
Contact Details
Address: 1300 South El Camino Real San Mateo, California United States | |
| Website | https://kronosbio.com |
Stock Details
| Ticker Symbol | KRON |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001741830 |
| CUSIP Number | 50107A104 |
| ISIN Number | US50107A1043 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Norbert W. Bischofberger Ph.D. | President, Chief Executive Officer & Director |
| Dr. Deborah A. Knobelman Ph.D. | Chief Operating Officer & Chief Financial Officer |
| Allison Frisbee J.D. | Chief Administrative Officer |
| David M. Tanen J.D. | Secretary & Director |
| Dr. Charles Lin Ph.D. | Chief Scientific Officer |
| Dr. Elizabeth A. Olek D.O., M.P.H. | Senior Vice President of Clinical Development |
| Dr. Margaux Bennett Ph.D. | Vice President of Corporate Development & Investor Relations |
| Joshua A. Kazam | Co-Founder & Director |
| Wes Trotter Ph.D. | Senior Vice President of Drug Discovery & Pharmaceutical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 07, 2024 | S-3 | Filing |
| Oct 15, 2024 | 4 | Filing |
| Oct 15, 2024 | 4 | Filing |
| Aug 08, 2024 | 8-K | Current Report |
| Aug 08, 2024 | 10-Q | Quarterly Report |